GSK778

• CAT Number: I014899
• CAS Number: 2451862-42-1
• Molecular Formula: C₃₀H₃₃N₅O₃
• Molecular Weight: 511.61
• Purity: ≥95%
• Target: Apoptosis
• Storage: Store at -20°C
• IUPAC Name: 4-[2-(methoxymethyl)-1-[(1R)-1-phenylethyl]-8-[[(3S)-pyrrolidin-3-yl]methoxy]imidazo[4,5-c]quinolin-7-yl]-3,5-dimethyl-1,2-oxazole
• InChI: InChI=1S/C30H33N5O3/c1-18-29(20(3)38-34-18)24-12-25-23(13-27(24)37-16-21-10-11-31-14-21)30-26(15-32-25)33-28(17-36-4)35(30)19(2)22-8-6-5-7-9-22/h5-9,12-13,15,19,21,31H,10-11,14,16-17H2,1-4H3/t19-,21+/m1/s1
• InChIKey: ZORLJXWXFABTPZ-CTNGQTDRSA-N
• SMILES: CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=N4)COC)[C@H](C)C5=CC=CC=C5)OC[C@H]6CCNC6

GSK778（Cat No.:I014899）is a selective inhibitor of the protein kinase ATR (ataxia telangiectasia and Rad3-related protein), which plays a crucial role in the cellular response to DNA damage and replication stress. By inhibiting ATR, GSK778 enhances the sensitivity of cancer cells to DNA-damaging agents, making it a valuable tool in cancer research and therapeutic development. This compound has shown promise in preclinical studies, particularly in enhancing the efficacy of chemotherapy and radiation treatments. GSK778’s unique mechanism provides insights into targeting DNA repair pathways, offering potential strategies for improving outcomes in various malignancies.

Reference

[1]. Omer G, et, al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020 Apr 24; 368(6489): 387-394.